BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 2809198)

  • 1. Immunosuppression and transforming growth factor-beta in glioblastoma. Preferential production of transforming growth factor-beta 2.
    Bodmer S; Strommer K; Frei K; Siepl C; de Tribolet N; Heid I; Fontana A
    J Immunol; 1989 Nov; 143(10):3222-9. PubMed ID: 2809198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protease inhibitors interfere with the transforming growth factor-beta-dependent but not the transforming growth factor-beta-independent pathway of tumor cell-mediated immunosuppression.
    Huber D; Philipp J; Fontana A
    J Immunol; 1992 Jan; 148(1):277-84. PubMed ID: 1727872
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The glioblastoma-derived T cell suppressor factor/transforming growth factor-beta 2 inhibits T cell growth without affecting the interaction of interleukin 2 with its receptor.
    Siepl C; Bodmer S; Frei K; MacDonald HR; De Martin R; Hofer E; Fontana A
    Eur J Immunol; 1988 Apr; 18(4):593-600. PubMed ID: 2452745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential expression of transforming growth factor-beta 1, -beta 2, and -beta 3 by glioblastoma cells, astrocytes, and microglia.
    Constam DB; Philipp J; Malipiero UV; ten Dijke P; Schachner M; Fontana A
    J Immunol; 1992 Mar; 148(5):1404-10. PubMed ID: 1538124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transforming growth factor-beta 2 down-regulates HLA-DR antigen expression on human malignant glioma cells.
    Zuber P; Kuppner MC; De Tribolet N
    Eur J Immunol; 1988 Oct; 18(10):1623-6. PubMed ID: 3142781
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Control of the expression of c-sis mRNA in human glioblastoma cells by phorbol ester and transforming growth factor beta 1.
    Press RD; Misra A; Gillaspy G; Samols D; Goldthwait DA
    Cancer Res; 1989 Jun; 49(11):2914-20. PubMed ID: 2655888
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of transforming growth factor beta 1 and its receptors during all-trans-retinoic acid (RA) treatment of RA-responsive human neuroblastoma cell lines.
    Cohen PS; Letterio JJ; Gaetano C; Chan J; Matsumoto K; Sporn MB; Thiele CJ
    Cancer Res; 1995 Jun; 55(11):2380-6. PubMed ID: 7757990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased expression of genes from growth factor signaling pathways in glioblastoma cell lines.
    Saxena A; Ali IU
    Oncogene; 1992 Feb; 7(2):243-7. PubMed ID: 1347915
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential expression of transforming growth factor beta receptors in human pancreatic adenocarcinoma.
    Venkatasubbarao K; Ahmed MM; Mohiuddin M; Swiderski C; Lee E; Gower WR; Salhab KF; McGrath P; Strodel W; Freeman JW
    Anticancer Res; 2000; 20(1A):43-51. PubMed ID: 10769633
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RNA interference targeting transforming growth factor-beta enhances NKG2D-mediated antiglioma immune response, inhibits glioma cell migration and invasiveness, and abrogates tumorigenicity in vivo.
    Friese MA; Wischhusen J; Wick W; Weiler M; Eisele G; Steinle A; Weller M
    Cancer Res; 2004 Oct; 64(20):7596-603. PubMed ID: 15492287
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Microglia-derived TGF-beta as an important regulator of glioblastoma invasion--an inhibition of TGF-beta-dependent effects by shRNA against human TGF-beta type II receptor.
    Wesolowska A; Kwiatkowska A; Slomnicki L; Dembinski M; Master A; Sliwa M; Franciszkiewicz K; Chouaib S; Kaminska B
    Oncogene; 2008 Feb; 27(7):918-30. PubMed ID: 17684491
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of transforming growth factor alpha in normal human adult kidney and enhanced expression of transforming growth factors alpha and beta 1 in renal cell carcinoma.
    Gomella LG; Sargent ER; Wade TP; Anglard P; Linehan WM; Kasid A
    Cancer Res; 1989 Dec; 49(24 Pt 1):6972-5. PubMed ID: 2582439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transforming growth factor beta production and responsiveness in normal human melanocytes and melanoma cells.
    Rodeck U; Bossler A; Graeven U; Fox FE; Nowell PC; Knabbe C; Kari C
    Cancer Res; 1994 Jan; 54(2):575-81. PubMed ID: 8275496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human glioma-induced immunosuppression involves soluble factor(s) that alters monocyte cytokine profile and surface markers.
    Zou JP; Morford LA; Chougnet C; Dix AR; Brooks AG; Torres N; Shuman JD; Coligan JE; Brooks WH; Roszman TL; Shearer GM
    J Immunol; 1999 Apr; 162(8):4882-92. PubMed ID: 10202033
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of TGF-beta 2 in human glioblastoma: a role in resistance to immune rejection?
    Fontana A; Bodmer S; Frei K; Malipiero U; Siepl C
    Ciba Found Symp; 1991; 157():232-8; discussion 238-41. PubMed ID: 1649035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo.
    Uhl M; Aulwurm S; Wischhusen J; Weiler M; Ma JY; Almirez R; Mangadu R; Liu YW; Platten M; Herrlinger U; Murphy A; Wong DH; Wick W; Higgins LS; Weller M
    Cancer Res; 2004 Nov; 64(21):7954-61. PubMed ID: 15520202
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role for transforming growth factor-beta (TGF-beta) in human cancer.
    Gold LI
    Crit Rev Oncog; 1999; 10(4):303-60. PubMed ID: 10654929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TGF-beta1 acts as a tumor suppressor of human malignant keratinocytes independently of Smad 4 expression and ligand-induced G(1) arrest.
    Paterson IC; Davies M; Stone A; Huntley S; Smith E; Pring M; Eveson JW; Robinson CM; Parkinson EK; Prime SS
    Oncogene; 2002 Feb; 21(10):1616-24. PubMed ID: 11896591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distinct effects of human glioblastoma immunoregulatory molecules programmed cell death ligand-1 (PDL-1) and indoleamine 2,3-dioxygenase (IDO) on tumour-specific T cell functions.
    Avril T; Saikali S; Vauleon E; Jary A; Hamlat A; De Tayrac M; Mosser J; Quillien V
    J Neuroimmunol; 2010 Aug; 225(1-2):22-33. PubMed ID: 20493562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transforming growth factor beta signaling is disabled early in human endometrial carcinogenesis concomitant with loss of growth inhibition.
    Parekh TV; Gama P; Wen X; Demopoulos R; Munger JS; Carcangiu ML; Reiss M; Gold LI
    Cancer Res; 2002 May; 62(10):2778-90. PubMed ID: 12019154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.